Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO
Jeff Jonas Remains As Chief Innovation Officer, Board Member
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
You may also be interested in...
The J.P. Morgan Healthcare Conference will be a virtual event but the industry's biggest business meeting will still lay the groundwork for the year ahead.
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.